Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (322)	10/3/1999 1:27:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1169

<<While I hope that 497 is best of breed, I'm actually still waiting to see who is going to win the HCV protease war.>> Just waiting and sitting, or doing little DD? This may become holy grain for next anti-viral drug. Geze, If one (or me) have answer on this question it will be a King among SI bio-freaks. One thing is for sure, lot of silence here, actually to much. So, something will move soon. What and from where, no idea. << I like IMPDH inhibitors for certain indications, but glad I don't need to take one. >> IMPDH inhibitor have its own problem. If I put here few IF, at the end 497 may look OK. Few indication that this IF shouldn't be so strong, but let first see results and than talk about. Miljenko